With Daniel N. Anziska, Daniel A. Ladow, Clark G. Sullivan
Product hopping accusations continue to make the headlines, most recently after the Attorney General for the State of New York (the "AG") brought an antitrust lawsuit against Actavis, PLC and its subsidiary Forest Laboratories, LLC (collectively "Forest") based on their marketing plans for Namenda ®, a hugely successful drug approved for the treatment of Alzheimer’s disease.